Effect of pegylation on pharmaceuticals
Related Experiment Video
Updated: Sep 27, 2026

Surface Passivation for Single-molecule Protein Studies
Published on: April 24, 2014
J Milton Harris1, Robert B Chess
1Nektar Therapeutics, 490 Discovery Drive, Huntsville, Alabama 35806, USA. jmharris@al.nektar.com
Abstract:
Protein and peptide drugs hold great promise as therapeutic agents. However, many are degraded by proteolytic enzymes, can be rapidly cleared by the kidneys, generate neutralizing antibodies and have a short circulating half-life. Pegylation, the process by which polyethylene glycol chains are attached to protein and peptide drugs, can overcome these and other shortcomings. By increasing the molecular mass of proteins and peptides and shielding them from proteolytic enzymes, pegylation improves pharmacokinetics. This article will review how PEGylation can result in drugs that are often more effective and safer, and which show improved patient convenience and compliance.
More Related Videos
15:33Microwave-assisted Functionalization of Poly(ethylene glycol) and On-resin Peptides for Use in Chain Polymerizations and Hydrogel Formation
Published on: October 29, 2013
06:56Particles without a Box: Brush-first Synthesis of Photodegradable PEG Star Polymers under Ambient Conditions
Published on: October 10, 2013
Related Concept Videos
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Drug Biotransformation: Overview
Pharmaceutical Equivalents